Jun 16, 2022 · We demonstrate that the CXCR3/CXCL9 chemokine axis is critical for IL-12 therapy and that temporal and spatial control of this axis via intratumoral expression of CXCL9 leads to productive immune responses with potent anti-tumor effects.

Feb 5, 2015 · Elevated IL-2R, IL-1RA, and CXCL9 are associated with shorter event-free survival in newly diagnosed FL, treated with chemoimmunotherapy. Increased serum IL-12 and IL-1RA is associated with shorter event-free survival in patients who were observed or …

Here we demonstrate that NHS-IL12 and entinostat synergize to produce potent antitumor efficacy in three αPD-1/αPD-L1 refractory tumor models harboring varying MHC-I/APM deficiencies, IFN-γ responsiveness, and TMB.

Apr 18, 2022 · In this study, we sought to understand if the addition of DNA-encodable CXCL9 could augment the anti-tumor immune responses driven by intratumoral IL-12. We show that localized IL-12 and CXCL9 treatment reshapes the tumor microenvironment to promote dendritic cell licensing and CD8 + T cell activation.

There were clear differences in the behaviour of monocytes and BAL macrophages in response to IL-12 and IL-18. Unstimulated BAL produced levels of the inflammatory chemokines CXCL8, CXCL9 and CXCL10 comparable to those present in IL-12- …

Feb 11, 2024 · Here, the discovery and characterization of multiple small-molecule enhancers of chemokine ligand 9 (CXCL9) and their targeted delivery in a TAM-avid systemic nanoformulation is reported.

Nov 15, 2022 · The interferon-response marker CXCL9 was shown to associate with any grade cGVHD, activation of IDO and increased activity of the kynurenine (Kyn) pathway. High interleukin (IL)-18 deviated the Kyn pathway to anthranilic and kynurenic acid, and this associated with severe fibrosing GVHD (1).

Jun 3, 2024 · Previous work has shown that the intratumoral electroporation of plasmid IL-12 and CXCL9 can elicit a potent antitumor immune response, increasing systemic antigen-specific CD8+ T cells and leading to the regression of both treated and untreated tumors.

Aug 15, 2020 · In the current study, we demonstrate that an enhanced CXCL9 gradient via intratumoral electroporation leads to efficient trafficking of CXCR3 + CD8 + T cells into CT26 tumors. We further explored how DNA-encodable IL-12/CXCL9 can work together to improve checkpoint inhibitor response.

We observe that the blockade of LIF in tumors expressing high levels of LIF decreases CD206, CD163 and CCL2 and induces CXCL9 expression in tumor-associated macrophages. The blockade of LIF releases the epigenetic silencing of CXCL9 triggering CD8 …